Avalo Therapeutics, Inc.
AVTX · XNASCIK 1534120fmd_15BSEZ369CF07MVZW79XPD481SManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 28 | 7 | 7 | 7 | 5 | 18 | 2 | 0 | 0 |
| Cost of revenue | 0 | 1 | 3 | (1) | 0 | 1 | 3 | 1 | – | – |
| Gross profit | 1 | 27 | 4 | 7 | 6 | 4 | 15 | 1 | – | – |
| Research and development | 10 | 4 | 6 | 12 | 32 | 60 | 31 | 14 | 24 | 50 |
| Selling, general and administrative | 7 | 9 | 11 | 12 | 20 | 25 | 21 | 10 | – | – |
| Total operating expenses | 17 | 14 | 58 | – | – | – | – | – | – | – |
| Operating income | (16) | 14 | (35) | (16) | (73) | (82) | (37) | (27) | (69) | (73) |
| Other non-operating income (expense) | (0) | (0) | 0 | 0 | 6 | (2) | (4) | (4) | 33 | (5) |
| Income before taxes | – | – | – | – | – | – | (42) | (32) | (35) | (78) |
| Income tax expense | 0 | 2 | (0) | 0 | (3) | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (35) | (16) | (64) | (84) | (42) | (32) | (35) | (78) |
| Net income | (16) | 12 | (40) | (16) | (63) | (84) | (42) | (32) | (35) | (78) |
| Net income to common shareholders | (16) | 8 | 42 | – | – | – | – | (32) | (35) | – |